EGFR and adenocarcinoma: The percentage appears to be high in Asia, where non-smoking lung cancer is associated with onset at a young age, advanced stage, adenocarcinoma histology, female gender, and specific EGFR/ ALK/ ROS-1 gene alterations that can be treated with targeted therapeutics [4-9].